Nevertheless, disappointing results from the clinical trials of EGFR-targeted therapies for CRC raise uncertainties about the significance of the EGFR signaling pathway in the patients specifically harboring KRAS, NRAS and BRAF mutations. Here, NRAS is linked to colorectal carcinoma.